Group One Trading’s Tempest Therapeutics TPST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-822
Closed -$35.6K 7499
2024
Q1
$41.8K Sell
822
-771
-48% -$39K ﹤0.01% 4861
2023
Q4
$91.1K Buy
+1,593
New +$75.4K ﹤0.01% 4546
2022
Q1
Sell
-15
Closed -$1K 8723
2021
Q4
$1K Sell
15
-101
-87% -$13.9K ﹤0.01% 8030
2021
Q3
$22K Buy
116
+54
+87% +$10.5K ﹤0.01% 7123
2021
Q2
$9K Buy
62
+60
+3,000% +$13.5K ﹤0.01% 7572
2021
Q1
$0 Sell
2
-115
-98% -$46.5K ﹤0.01% 8027
2020
Q4
$49K Hold
117
﹤0.01% 5026
2020
Q3
$37K Sell
117
-8
-6% -$2.71K ﹤0.01% 4829
2020
Q2
$43K Sell
125
-102
-45% -$40.7K ﹤0.01% 4458
2020
Q1
$234K Buy
227
+127
+127% +$185K ﹤0.01% 2629
2019
Q4
$132K Buy
+100
New +$141K ﹤0.01% 3466
2017
Q1
Sell
-3
Closed -$13K 5004
2016
Q4
$13K Buy
+3
New +$37.4K ﹤0.01% 3874
2016
Q3
Sell
-1
Closed -$18.1K 4908
2016
Q2
$11K Buy
+1
New +$22.8K ﹤0.01% 4046
2016
Q1
Sell
-2
Closed -$42.3K 4951
2015
Q4
$67K Sell
2
-21
-91% -$692K ﹤0.01% 3249
2015
Q3
$576K Buy
23
+12
+109% +$808K 0.01% 1658
2015
Q2
$945K Buy
11
+10
+1,000% +$916K 0.01% 1253
2015
Q1
$122K Buy
+1
New +$133K ﹤0.01% 2757

Other funds holding TPST

Group One Trading's TPST Position: Q2 2024 in Review

Group One Trading sold out of Tempest Therapeutics (TPST) in Q2 2024, closing a stake of 822 shares — an estimated $35.6K sold.

Group One Trading first reported a position in TPST in Q1 2015 and held it in 17 quarters. The position peaked at $945K in Q2 2015. 24 funds tracked by Wall St. Rank hold TPST as of Q2 2024.

  • Group One Trading reported no remaining Tempest Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Group One Trading sold 822 Tempest Therapeutics shares in Q2 2024, an estimated $35.6K.
  • Group One Trading first reported a position in Tempest Therapeutics in Q1 2015 and held it in 17 quarters.
  • Group One Trading's Tempest Therapeutics position peaked at $945K in Q2 2015.
  • 24 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2024.

Based on Group One Trading's 13F filing for Q2 2024, filed 14 Aug 2024.